Enoxaparin Sodium Market Size, Share, Growth, and Industry Analysis, By Type (20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL, 120mg/0.8mL, 150mg/1mL & 300mg/3mL.), By Application (Hospital, Clinic & Others) and Regional Forecast to 2032

Updated On: 04 November 2024

• 

  Request a Free Sample to learn more about this report

ENOXAPARIN SODIUM MARKET REPORT OVERVIEW

The global Enoxaparin Sodium Market Size was USD 3.04 billion in 2023 and the market is projected to touch USD 6.80 billion by 2032, exhibiting a CAGR of 8.3% during the forecast period.

The distribution of this low molecular weight heparin by global pharmaceutical companies is a major force driving segmentation in the enoxaparin market. Enoxaparin sodium is mainly indicated for preventing and treating deep vein thrombosis and pulmonary embolism; thus, it is an integral part in the management of cardiovascular disease. Market trends currently involve the increased availability of generic versions of enoxaparin sodium, hence standardization of the drug at an affordable price. Companies are ceaselessly trying to capture the availability supply chain of products that are capable of meeting the variable demand of global healthcare systems by incessantly molding the market outlook with the evolving dynamics in manufacturing and regulatory clearances.

COVID-19 Impact: surge in cases with clotting disorders led to a rising demand

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic contributed to increasing the demand for Enoxaparin Sodium. Major drug use is in the management of clotting disorders associated with the severe form of the infection. Increased demand, hence touting anticoagulants in the treatment protocols, guaranteed increased production and put them at par in the market presence of Enoxaparin Sodium during the pandemic.

LATEST TRENDS

"Adoption of generic formulation has reduced consumer expense and advancements in drug delivery has enhanced patient comfort"

Recent trends in the enoxaparin sodium market growth include increased need for its generic formulations, which have started to make the drug available to more patients, hence reducing their costs. Added to this are some new routes of administration introduced into the market, such as prefilled syringes plus autoinjectors, offering not only convenience but also improved compliance. Other market drivers include an increase in research and studies for enoxaparin sodium's efficacy in a number of other uses apart from that for which it is traditionally meant, because of the prevalent clinical trials presently underway. They are therefore global trends intended to indicate an upturn in the market with directions to the administration of enoxaparin sodium.

• 

  Request a Free Sample to learn more about this report

ENOXAPARIN SODIUM MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL, 120mg/0.8mL, 150mg/1mL and 300mg/3mL.

• 40mg/0.4mL: This is commonly used for regular prophylaxis in hospitalized patients and those undergoing surgery.
• 60mg/0.6mL: This is required in those patients needing high doses for treating acute coronary syndrome.
• 80mg/0.8mL: Commonly used in severe conditions like extensive thromboembolic disorders.
• 100mg/1mL: This dose is given in high doses of the treatment protocol and few critical cares.
• 120mg/0.8ml: This is used in some therapeutic protocols that need very.
• 150mg/1mL: Generally used in more aggressive anticoagulation therapies, where the cases may be more complicated.
• 300mg/3mL: Given in high-dose treatments or special protocols, mostly in hospitals.

By Application

Based on application the global market can be categorized into hospital, clinic and others.

• Hospital: Enoxaparin sodium is primarily used in hospitals for the treatment of any acute situation like DVT, pulmonary embolism, and for post-surgical prophylaxis.
• Clinic: It is significantly used in clinics for patients in outpatient departments at risk of thromboembolic events and routine prophylaxis.
• Others: A good number of settings from long-term care facilities, home healthcare to specialized treatment centers, which use enoxaparin sodium for different therapeutic needs.

DRIVING FACTORS

"Rising prevalence of cardiovascular diseases boost market growth"

Increase in incidences of cardiovascular diseases such as DVT and PE are the major factors responsible in propelling enoxaparin sodium market growth. Growing incidences of cardiovascular diseases due to the aging population, increasing surgical volume, and a sedentary lifestyle are increasing the demand for effective anticoagulants. It emphasizes greatly the critical role enoxaparin sodium has in the prophylaxis of thromboembolic events and has significantly facilitated increased drug usage.

"Expansion of generic formulations to increase market extent"

A generic form of enoxaparin sodium has been available on the market and has impacted it to a significant extent, being both more affordable price-wise and, at the same time, available. Because it represents a cost-effective alternative to branded products, the cost of health is then dramatically reduced while extending access to treatment to patients. Entry of several generic manufacturers has increased competition and reduced prices, with more extensive availability. This expansion is driven by regulatory approvals and the expiration of patents on branded versions, thereby making the enoxaparin sodium option more pervasively available in both hospitals and outpatient settings. The growth of generics has thus played a critical role in boosting the overall market penetration for enoxaparin sodium.

RESTRAINING FACTORS

"Regulatory and reimbursement challenges may restrain market growth "

Significant restraining factors in the enoxaparin sodium market are the regulatory and reimbursement challenges. Major regulatory challenges include stringent approval procedures and requirements for large clinical trials which might cause delay of new formulations or generics entry into the market and affect availability and competition among different products. However, inability to access it by different policies of reimbursing it in different localities may adversely affect the overall adoption rate of the drug. Unequal rates of reimbursement and limitations in coverage present financial roadblocks to both patients and health care providers, which will, in turn, lead to a decrease in the market potential for this drug. All these thus challenge the markets, which will likely tie down growth and affect market development.

• 

  Request a Free Sample to learn more about this report

ENOXAPARIN SODIUM MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America dominates global market driven by advanced healthcare infrastructure "

The North America region held the major enoxaparin sodium market share. This dominance is driven by advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and significant investments in research and development. In addition to this, this region also hosts major pharmaceutical companies and strong regulatory frameworks, which provide a stronghold in the market. The U.S. is one of the key markets for Enoxaparin Sodium, wherein the demand for effective anticoagulants is very high.

KEY INDUSTRY PLAYERS 

"With strategic efforts to meet changing consumer needs, the key industry players continue to dominate the markets"

The major payers in the enoxaparin sodium market are reportedly doing some strategic initiatives for a better foothold in the marketplace and refinement of product lines. With an impetus on diversification of the product basket towards new and more advanced formulations in terms of generics, alternative delivery systems, and based on diversified needs of other products, it means an increase in investments for research and development in order to optimize the efficacy and safety of drugs and to develop new therapeutic indications. Besides that, streamlining production processes and improving supply chain logistics address market needs more effectively. Other imperatives in the area of improving market competence, hence maintaining a competitive advantage, involve partnerships with healthcare providers and involvement in clinical trials.

List of Market Players Profiled

• Sanofi (France)
• Teva (Israel)
• Techdow (Hepalink) (China)
• Fresenius Kabi (Germany)
• Rovi (Spain)
• Amphastar (United States)
• Nanjing King-friend (China)
• Sandoz (Switzerland)
• Apotex (Canada)
• Hangzhou Jiuyuan Gene Engineering (China)
• Cipla (India)
• Taj Pharma (India)
• Chengdu Baiyu Pharmaceutical (China)
• Suzhou Erye Pharmaceutical (China)
• Changzhou Qianhong Bio-pharma (China)
• Hebei Changshan Biochemical Pharmaceutical (China)
• Beijing SL Pharmaceutical (China)
• Huadong Medicine (China)
• Bharat Serums (India)
• INTAS (India)
• LUPIN (India)
• Troikaa Pharmaceuticals (India)
• Aristopharma (Bangladesh)
• Fosun Pharma (China)
• SciencePharma (India)
• PISA (Brazil)

INDUSTRIAL DEVELOPMENT

July 2024: Amphastar Pharmaceuticals announced that the FDA approved a new generic version of enoxaparin sodium. This increase to their product line further cements their place in the anticoagulant market.

REPORT COVERAGE

The report elaborates on the general market dynamics, drivers, and restraints of the enoxaparin sodium market. In addition to this, it has segmented the market in respect to type and application, such as trends pertaining to the growing popularity of generic formulations and new drug delivery systems. It expands on post-COVID-19 growth assessments of the market, delineates key players within the industry, and comes up with regional insights, whereby North America is at the top. It gives an outlook for the market through 2030, including major developments—specifically those approved by the FDA—expected over that time period.